● Recruiting

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Condition: Advanced Solid Tumors With MAPK Pathway Mutations · Sponsor: D3 Bio (Wuxi) Co., Ltd

PhasePhase 1/Phase 2

Planned participants67

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations.

This description comes directly from the study's public registry record.

Talk to the study team

Medical Director · +86 21 61635900 · D3bio_CT@d3bio.com

Always discuss trial participation with your own doctor first.

Locations (14)

D3 Bio Investigative Site	Detroit, Michigan, United States	Recruiting
D3 Bio Investigative Site	New York, New York, United States	Completed
D3 Bio Investigative Site	Nashville, Tennessee, United States	Recruiting
D3 Bio Investigative Site	Blacktown, New South Wales, Australia	Completed
D3 Bio Investigative Site	Macquarie Park, New South Wales, Australia	Recruiting
D3 Bio Investigative Site	Bedford Park, South Australia, Australia	Completed
D3 Bio Investigative Site	Nedlands, Western Australia, Australia	Completed
D3 Bio Investigative Site	Beijing, Beijing Municipality, China	Recruiting
D3 Bio Investigative Site	Guangzhou, Guangdong, China	Recruiting
D3 Bio Investigative Site	Harbin, Heilong Jiang, China	Completed
D3 Bio Investigative Site	Wuhan, Hubei, China	Recruiting
D3 Bio Investigative Site	Shanghai, Shanghai Municipality, China	Active Not Recruiting

+ 2 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05886920